TTY Biopharm Past Earnings Performance

Past criteria checks 3/6

TTY BiopharmDie Erträge des Sektors -5.8% sind im Durchschnitt pro Jahr zurückgegangen, während die Erträge des Sektors Pharmaceuticals growing auf 18.5% pro Jahr stiegen. Die Einnahmen waren growing mit einer durchschnittlichen Rate von 5.2% pro Jahr. TTY Biopharm Die Eigenkapitalrendite des Unternehmens beträgt 18.4%, und die Nettomargen liegen bei 21.7%.

Key information

-2.0%

Earnings growth rate

-2.0%

EPS growth rate

Pharmaceuticals Industry Growth	18.5%
Revenue growth rate	5.7%
Return on equity	17.2%
Net Margin	20.5%
Last Earnings Update	31 Dec 2023

Recent past performance updates

Recent updates

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Apr 02

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

Mar 15

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Feb 25

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

Feb 07

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

Jan 19

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 10

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

Dec 15

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

Nov 25

Revenue & Expenses Breakdown
Beta

How TTY Biopharm makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TPEX:4105 Revenue, expenses and earnings (TWD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	5,506	1,129	1,599	310
30 Sep 23	5,394	1,168	1,543	293
30 Jun 23	5,287	1,130	1,546	312
31 Mar 23	5,191	1,106	1,515	345
31 Dec 22	5,062	1,094	1,440	353
30 Sep 22	4,997	1,193	1,396	350
30 Jun 22	4,731	1,109	1,360	323
31 Mar 22	4,609	856	1,340	295
31 Dec 21	4,536	832	1,338	288
30 Sep 21	4,270	751	1,330	267
30 Jun 21	4,235	720	1,382	251
31 Mar 21	4,092	874	1,365	253
31 Dec 20	4,222	924	1,388	262
30 Sep 20	4,130	693	1,405	274
30 Jun 20	4,255	787	1,369	295
31 Mar 20	4,445	860	1,402	300
31 Dec 19	4,466	900	1,375	299
30 Sep 19	4,447	1,236	1,305	320
30 Jun 19	4,204	1,263	1,264	324
31 Mar 19	4,110	1,499	1,253	358
31 Dec 18	4,036	1,461	1,242	361
30 Sep 18	4,102	1,696	1,225	332
30 Jun 18	4,240	1,631	1,210	331
31 Mar 18	4,173	1,379	1,161	294
31 Dec 17	4,079	1,345	1,116	296
30 Sep 17	3,874	1,088	1,097	322
30 Jun 17	3,765	1,023	1,079	321
31 Mar 17	3,795	1,134	1,063	340
31 Dec 16	3,761	1,193	1,038	342
30 Sep 16	3,733	1,536	1,055	354
30 Jun 16	3,612	1,565	1,035	337
31 Mar 16	3,389	1,393	1,048	317
31 Dec 15	3,195	1,211	1,053	340
30 Sep 15	3,058	1,133	1,060	328
30 Jun 15	2,929	986	1,080	348
31 Mar 15	2,969	829	1,132	370
31 Dec 14	2,980	780	1,191	369
30 Sep 14	2,976	196	1,234	394
30 Jun 14	2,995	94	1,312	400
31 Mar 14	2,957	124	1,315	390
31 Dec 13	3,110	587	1,325	384
30 Sep 13	3,262	702	1,341	392
30 Jun 13	3,442	711	1,330	403

Qualität der Erträge: 4105 hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: 4105Die aktuellen Gewinnspannen (21.7%) sind niedriger als im letzten Jahr (23.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Ergebnisentwicklung: 4105Die Erträge des Unternehmens sind in den letzten 5 Jahren um 5.8% pro Jahr zurückgegangen.

Beschleunigtes Wachstum: 4105Das Gewinnwachstum des Unternehmens im letzten Jahr (3.1%) übertrifft seinen 5-Jahres-Durchschnitt (-2% pro Jahr).

Erträge im Vergleich zur Industrie: 4105 Das Gewinnwachstum im vergangenen Jahr (3.1%) übertraf das der Branche Pharmaceuticals -8.3% .

Return on Equity

Hohe Eigenkapitalrendite: 4105Die Eigenkapitalrendite des Unternehmens (18.4%) wird als niedrig angesehen.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

TTY Biopharm Past Earnings Performance

Past criteria checks 3/6

Key information

Recent past performance updates

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2023 earnings: EPS exceeds analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Recent updates

Upcoming dividend of NT$3.50 per share

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Dividend increased to NT$3.50

TTY Biopharm Company Limited Announces Change of CFO and Financial Officer

TTY Biopharm Company Limited, Annual General Meeting, May 30, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 10% to NT$86.00

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS exceeds analyst expectations

Price target increased by 14% to NT$84.50

TTY Biopharm Company Limited Announces Decision Rendered by the Supreme Court for Validity of the Risperidone Development Agreement Between the Company and Center Laboratories, Inc

Now 20% undervalued after recent price drop

Upcoming dividend of NT$3.40 per share at 4.3% yield

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to NT$71.50

Price target increased to NT$79.50

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

TTY Biopharm Company Limited Announces Internal Audit Officer Changes, Effective November 7, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of NT$3.00 per share

TTY Biopharm Company Limited Announces Dividend Distribution, Payable on August 15, 2022

TTY Biopharm Company Limited Announces Cash Dividend for the Year 2021

Price target decreased to NT$73.00

Less than half of directors are independent

TTY Biopharm Company Limited Announces the Resignation of Chou,Te-Yu as Member of Remuneration Committee

Price target decreased to NT$73.67

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Third quarter 2021 earnings released: EPS NT$1.02 (vs NT$0.90 in 3Q 2020)

Upcoming dividend of NT$4.00 per share

Price target increased to NT$80.00

Consensus EPS estimates fall to NT$2.87

Second quarter 2021 earnings released: EPS NT$0.13 (vs NT$0.75 in 2Q 2020)

Price target increased to NT$80.20

Price target increased to NT$80.20

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$0.82 (vs NT$1.02 in 1Q 2020)

Here's Why TTY Biopharm (GTSM:4105) Can Manage Its Debt Responsibly

Tty Biopharm Company Limited Proposes Dividend for the Period January 1, 2020 to December 31, 2020

Full year 2020 earnings released: EPS NT$3.72 (vs NT$3.62 in FY 2019)

Is There An Opportunity With TTY Biopharm Company Limited's (GTSM:4105) 43% Undervaluation?

PAION AG Enters into License Agreement with TTY Biopharm Company Limited

Are Dividend Investors Making A Mistake With TTY Biopharm Company Limited (GTSM:4105)?

Price target lowered to NT$73.50

TTY Biopharm Company Limited (GTSM:4105) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?

TTY Biopharm Company Limited, Annual General Meeting, Jun 09, 2021

New 90-day low: NT$61.40

TTY Biopharm Company Limited (GTSM:4105) Analysts Just Cut Their EPS Forecasts Substantially

New 90-day low: NT$68.10

What Type Of Returns Would TTY Biopharm's(GTSM:4105) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

TTY Biopharm (GTSM:4105) Has A Pretty Healthy Balance Sheet

How Does TTY Biopharm Company Limited (GTSM:4105) Fare As A Dividend Stock?

TTY Biopharm Company Limited Announces Executive Changes, with Effect from January 20, 2021

Revenue and earnings beat expectations

Third quarter 2020 earnings released: EPS NT$0.89

Market bids up stock over the past week

New 90-day high: NT$84.30

Analysts lower revenue estimates to NT$4.14b

New 90-day low: NT$66.20

Price target lowered to NT$79.33

New 90-day low - NT$68.70

First half earnings released

First half earnings released

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Revenue & Expenses Breakdown
Beta